Resverlogix’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Resverlogix is a biotechnology company that researches, develops and commercializes BET inhibitors for the treatment of chronic diseases. Read more

Donald McCaffrey's photo - President & CEO of Resverlogix

President & CEO

Donald McCaffrey

CEO Approval Rating

80/100

Founded:

2001

Status:

PublicTMX Group - Toronto Stock ExchangeRVX

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Zenith Epigenetics is perceived as one of Resverlogix's biggest rivals. Zenith Epigenetics was founded in 2013 in Calgary, Alberta. Zenith Epigenetics is in the Biotechnology field. Zenith Epigenetics generates $1.8M more revenue than Resverlogix.

Aptose is Resverlogix's #2 rival. Aptose is a Public company that was founded in 1986 in San Diego, California. Aptose competes in the Biotechnology industry. Compared to Resverlogix, Aptose has 4 more employees.

Constellation Pharmaceuticals is one of Resverlogix's top competitors. Constellation Pharmaceuticals's headquarters is in Cambridge, Massachusetts, and was founded in 2008. Like Resverlogix, Constellation Pharmaceuticals also operates in the Pharmaceuticals industry. Constellation Pharmaceuticals generates 145% of Resverlogix's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Pharmaxis a competitor of Resverlogix?

Quarterly and Annual Revenue

Coming soon for Resverlogix!

Annual Revenue

$3.2M

Resverlogix's revenue is the ranked 20th among it's top 10 competitors. The top 10 competitors average 60.9M.

Acquisitions

No recent acquisitions found related to Resverlogix

Resverlogix Funding History

$25M$37.3M$87.3M$174.3M$234.6M$239.6M$241.6M

Since Resverlogix was founded in 2001, it has participated in 10 rounds of funding. In total Resverlogix has raised $241.6M. Resverlogix's last funding round was on Aug 2020 for a total of $2.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Aug 2020
$2M
-
Private Placement
Jan 2019
$5M
-
Private Placement
Nov 2018
$10.3M
-
Private Placement
Aug 2018
$20M
-
Debt
May 2018
$30M

Total Funding: $241.6M

Since Resverlogix was founded in 2001, it has participated in 10 rounds of funding. In total Resverlogix has raised $241.6M. Resverlogix's last funding round was on Aug 2020 for a total of $2.0M

Investments

No recent investments found related to Resverlogix

Resverlogix News

July 21, 2020BioSpace

Resverlogix Secures One-Year Extension of Maturity Date of Debenture

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed a one... See more »
June 6, 2020Unique Finance

Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020

Email Print Friendly Share CALGARY, Alberta, June 05, 2020 (GLOBE NEWSWIRE) - Resverlogix Corp. ("Res... See more »
June 1, 2020FirstWord Pharma

Resverlogix Plans COVID-19 Clinical Trial Program Launch

CALGARY, Alberta, June 01, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company"... See more »
March 31, 2020Benzinga

Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual

BETonMACE shows apabetalone treatment was associated with 41% reduction in hospitalizations for heart... See more »
March 24, 2020FE Investegate

Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication

12:00 PM: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Re... See more »
March 24, 2020firstword pharma

Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce a March 23, 2020 ... See more »
March 23, 2020FE Investegate

Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research

11:00 AM: Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat t... See more »

Resverlogix Blogs

September 22, 2016RESVERLOGIX Blog

Resverlogix's Poster Presentation and eVideo from the EASD

On September 14, 2016, Dr. Norman Wong, Chief Scientific Officer of Resverlogix Corp. presented an ab... See more »
July 8, 2016RESVERLOGIX Blog

RESVERLOGIX FEATURED IN THE EPIGENETICS SYMPOSIUM AT NEW YORK ACADEMY OF SCIENCE

Resverlogix recently participated in the symposium, Epigenetics: Cancer and Beyond, at the New York A... See more »
March 30, 2016RESVERLOGIX Blog

New CEO Video Presentation

On March 23, 2016, Resverlogix's President and Chief Executive Officer Donald McCaffrey had the oppor... See more »
March 29, 2016RESVERLOGIX Blog

Sanofi Biogenius Competition - CTV News feature

Resverlogix is committed to community investment. As a scientific leader in our field, we believe it ... See more »
February 25, 2016RESVERLOGIX Blog

Pharmacoeconomics

With the aging population and increased prevalence of chronic diseases, such as cardiovascular diseas... See more »
February 17, 2016RESVERLOGIX Blog

2016 Outlook: A video message from President & CEO Donald McCaffrey

President & CEO Donald McCaffrey was interviewed by Executive Video at the J.P. Morgan 34th Annual He... See more »
December 22, 2015RESVERLOGIX Blog

Current Treatments for Complement Mediated Diseases

Over the past few months, we have detailed a blog series on the Complement System. Recent posts highl... See more »

Resverlogix Press Releases

March 30, 2020GlobeNewswire

Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

Announces publication of accompanying JAMA editorial highlighting important secondary endpoints inclu... See more »
April 1, 2019GlobeNewswire

Resverlogix Announces $15.1 Million of Private Placements

CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company... See more »
March 27, 2019GlobeNewswire

Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone

BETonMACE trial to continue as planned without modificationBETonMACE trial to continue as planned wit... See more »
March 11, 2019GlobeNewswire

Resverlogix Announces Participation at Prominent Industry and Investor Conferences

CALGARY, Alberta, March 11, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company... See more »
December 19, 2018GlobeNewswire

Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone

BETonMACE trial to continue as planned without modificationBETonMACE trial to continue as planned wit... See more »
November 28, 2018GlobeNewswire

Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal

New evidence supporting the benefit of selective BET inhibition in the treatment of cardiovascular di... See more »
March 19, 2018StreetInsider

RVX)

Resverlogix Corp., based in Calgary, Canada, and San Francisco, CA, is in the advanced clinical stage... See more »

Headquarters

300, 4820 Richard Road SW

Calgary, AlbertaT3E 6L1

403-254-9252

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Resverlogix is a biotechnology company that researches, develops and commercializes BET inhibitors for the treatment of chronic diseases. Resverlogix was founded in 2001. Resverlogix's headquarters is located in Calgary, Alberta, CA T3E 6L1. It has ra...

CEO

Resverlogix's President & CEO, Donald McCaffrey, currently has an approval rating of 80%. Resverlogix's primary competitors are Zenith Epigenetics, Aptose & Constellation Pharmaceuticals.

Website

resverlogix.com

Frequently Asked Questions about Resverlogix

  1. When was Resverlogix founded?

    Resverlogix was founded in 2001
  2. Who is Resverlogix's CEO?

    Resverlogix's CEO is Donald McCaffrey
  3. How much revenue does Resverlogix generate?

    Resverlogix generates $3.2M in revenue
  4. How much funding does Resverlogix have?

    Resverlogix has historically raised $241.6M in funding
  1. Where is Resverlogix's headquarters?

    Resverlogix's headquarters is in Calgary Alberta, CA
  2. How many employees does Resverlogix have?

    Resverlogix has 27 employees
  3. What sector does Resverlogix operate in?

    Resverlogix is in Pharmaceuticals
  4. Who are Resverlogix's competitors?

    Resverlogix's top competitors are Zenith Epigenetics, Aptose, Constellation Pharmaceuticals